Knights of Columbus Asset Advisors LLC Takes Position in Guardant Health, Inc. $GH

Knights of Columbus Asset Advisors LLC purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,876 shares of the company’s stock, valued at approximately $1,554,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Signaturefd LLC grew its holdings in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares during the period. IFP Advisors Inc grew its holdings in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after buying an additional 334 shares in the last quarter. Allworth Financial LP raised its holdings in Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after acquiring an additional 552 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of Guardant Health in the third quarter valued at approximately $38,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Guardant Health during the 2nd quarter valued at about $62,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GH. JPMorgan Chase & Co. upped their price objective on Guardant Health from $90.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Piper Sandler lifted their price objective on shares of Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. UBS Group restated a “buy” rating and set a $175.00 price target on shares of Guardant Health in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Finally, Citigroup boosted their target price on Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $106.86.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 90,565 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the sale, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. This represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $104.04, for a total value of $567,122.04. Following the completion of the transaction, the chief technology officer directly owned 7,012 shares of the company’s stock, valued at approximately $729,528.48. This trade represents a 43.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 445,123 shares of company stock worth $46,600,702. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $114.04 on Friday. The stock has a market capitalization of $14.37 billion, a P/E ratio of -35.53 and a beta of 1.58. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74. The company’s fifty day moving average is $106.57 and its two-hundred day moving average is $79.82.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same period in the previous year, the business posted ($0.88) earnings per share. The company’s revenue was up 38.5% on a year-over-year basis. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.